Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.

Participants needed: 100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Trevi TherapeuticsUpdated: Jun 26, 2026
Eligibility criteria

Insufficient improvement in cough after treatment for any identified cough-assoc... [+5]

Clinical diagnosis of sleep apnea and/or use of continuous positive airway press... [+9]

Read more
Status: Not yet recruiting

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).

Participants needed: 306
Trial details
Phase: Phase 3Age: 40+Biological sex: AllType: InterventionalSponsor: Trevi TherapeuticsUpdated: Jun 26, 2026
Eligibility criteria

Diagnosis of IPF as determined by the Investigator based on American Thoracic So... [+5]

Clinical diagnosis or clinical suspicion of an upper or lower respiratory tract... [+2]

Read more
Status: Recruiting

NAL ER IPF Respiratory Function and Safety Study

The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.

Participants needed: 10
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Trevi TherapeuticsUpdated: Apr 9, 2026Locations: 2
Eligibility criteria

Diagnosis of IPF as determined by a pulmonologist based on American Thoracic Soc... [+2]

Exacerbation of IPF in the last 3 months. [+6]

Read more
Status: Recruiting

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

The primary purpose of this study is to evaluate the effect of a high-fat, high-calorie meal on the relative bioavailability of NAL ER following single oral doses.

Participants needed: 60
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Trevi TherapeuticsUpdated: Mar 23, 2026Locations: 1
Eligibility criteria

Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kilogram per meter square (kg/m2) at Scr... [+1]

Positive results for coronavirus infection (COVID-19) at Screening or check-in (... [+8]

Read more